The drug uses Medincell’s proprietary technology to provide a controlled, steady release of olanzapine, which is commonly used as a treatment for schizophrenia but is tied to the risk of post-injection delirium or sedation syndrome (PDSS).
The companies said there were no cases of PDSS reported in the study.
PDSS causes a sudden and unexpected onset of delirium or sedation within the first several hours of treatment and is associated with long-acting injections administered into a muscle.